What are effective program characteristics of self-management interventions in patients with heart failure? An individual patient data meta-analysis

Nini H. Jonkman, Heleen Westland, Rolf H.H. Groenwold, Susanna Ågren, Manuel Anguita, Lynda Blue, Pieta W.F. Bruggink-André de la Porte, Darren A. DeWalt, Paul L. Hebert, Michele Heisler, Tiny Jaarsma, Gertrudis I.J.M. Kempen, Marcia E. Leventhal, Dirk J.A. Lok, Jan Mårtensson, Javier Muñiz, Haruka Otsu, Frank Peters-Klimm, Michael W. Rich, Barbara Riegel, Anna Strömberg, Ross T. Tsuyuki, Jaap C.A. Trappenburg, Marieke J. Schuurmans, Arno W. Hoes

Supplementary material

DETAILS ON THE SENSITIVITY ANALYSES

Several sensitivity analyses were performed to assess robustness of findings from the primary univariable analysis reported in the manuscript.

First, the univariable approach described in the *Statistical analysis* section in the manuscript did not allow adjustment for other program characteristics, which may introduce confounding by correlation with other characteristics. The number of included studies (N=20) was insufficient for a comprehensive analysis including all characteristics simultaneously in a mixed effects model, as initially intended. To confirm the effects found in the univariable analysis, an observational multivariable analysis was performed as sensitivity analysis. We used the regression models described in the *Statistical analysis* section to estimate treatment effects, but excluded random effects or frailty term. The regression models included all program-specific covariates and a dummy variable indicating study, and were adjusted for sex and age of individual patients.

Second, a complete-case analysis was carried out to assess the effect of imputing data and analyses were repeated by excluding the largest trial. A final sensitivity analysis was performed in which the published main effects of eligible trials that did not provide individual patient data were pooled with the main effects of the individual patient data meta-analysis to assess the impact of missing trials on our findings.

Table S1: Search strategy for PubMed.

(("heart failure" [MeSH Terms] OR CHF [Title/Abstract] OR HF [Title/Abstract] OR "congestive heart failure" [Title/Abstract] OR "chronic cardiac failure" [Title/Abstract] OR "congestive cardiac failure" [Title/Abstract] OR "heart failure" [Title/Abstract] OR "cardiac failure" [Title/Abstract] OR "heart decompensation" [Title/Abstract])

AND (self-management[MeSH Terms] OR self-care[MeSH Terms] OR patient-education[MeSH Terms] OR "behavior therapy" [MeSH Terms] OR self-manag* [Title/Abstract] OR self-car* [Title/Abstract] OR self-monitor* [Title/Abstract] OR self-administration [Title/Abstract] OR self-medication [Title/Abstract] OR educate [Title/Abstract] OR education [Title/Abstract] OR educating [Title/Abstract] OR educational [Title/Abstract] OR instruction [Title/Abstract] OR instructions [Title/Abstract] OR instructional [Title/Abstract] OR trained [Title/Abstract] OR "action plan*" [Title/Abstract] OR patient-educat* [Title/Abstract] OR patient-cent* [Title/Abstract] OR patient-focus* [Title/Abstract] OR "behavior therapy" [Title/Abstract] OR "empowerment [Title/Abstract])

AND ("randomized controlled trial" [MeSH Terms] OR "randomised controlled trial" [MeSH Terms] OR "controlled clinical trial" [MeSH Terms] OR "random allocation" [MeSH Terms] OR "evaluation studies" [MeSH Terms] OR "intervention studies" [MeSH Terms] OR "randomized controlled trial" [Title/Abstract] OR "randomised controlled trial" [Title/Abstract] OR "clinical trial" [Title/Abstract] OR "clinical trial" [Title/Abstract] OR "random allocation" [Title/Abstract] OR intervention [Title/Abstract] OR trial [Title/Abstract] OR random [Title/Abstract] OR randomized [Title/Abstract] OR randomized [Title/Abstract] OR randomization [Title/Abstract] OR randomizing [Title/Abstract] OR randomizing [Title/Abstract] OR allocation [Title/Abstract]

Table S2: Missing values for baseline variables and outcomes for each study included in the individual patient data meta-analysis.

| | $\begin{array}{l} \textbf{Agren,} \\ 2012^{29} \end{array}$ | Aldamiz, 2007^{30} | Atienza, 2004 ³¹ | Blue, 2001 ³² | Bruggink, 2007 ³³ | DeWalt, 2012 ⁷ | Heisler, 2013 ³⁴ | Jaarsma, 1999 ³⁵ | Jaarsma, 2008 ⁶ | Leventhal, 2011 ³⁶ | Martensson, 2005 ³⁷ | Otsu, 2011 ³⁸ | PetersKlimm, 2010^{39} | Rich, 1995 ⁴⁰ | Riegel, 2002 ⁴¹ | Riegel, 2006 ⁴² | Sisk, 2006 ⁴³ | Smeulders, 2009 ^{44,45} | Stromberg, 2003 ⁴⁶ | Tsuyuki, 2004 ⁴⁷ |
|--|---|----------------------|--------------------------------|--------------------------|---------------------------------|----------------------------------|--------------------------------|--------------------------------|-------------------------------|----------------------------------|-----------------------------------|--------------------------|--------------------------|--------------------------|-------------------------------|-------------------------------|--------------------------|-------------------------------------|----------------------------------|--------------------------------|
| | n=155 | n=279 | n=338 | n=165 | n=240 | n=605 | n=266 | n=179 | n=1023 | n=42 | n=153 | n=102 | n=197 | n=282 | n=358 | n=135 | n=406 | n=317 | n=106 | n=276 |
| Baseline characteristics | | | | | | | | | | | | | | | | | | | | |
| Sex | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Age | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| LVEF | NA | 27(9.7%) | 30(8.9%) | NA | 18(7.5%) | 18(3.0%) | NA | 0 (0%) | 96(9.4%) | 1 (2.4%) | NA | NA | 26 (13.2%) | 60 (21.3%) | 154 (43.0%) | 29 (21.5%) | NA | NA | NA | 94 (34.1%) |
| NYHA Class | 1 (0.6%) | 0 (0%) | 0 (0%) | 2 (1.2%) | 1 (0.4%) | 0 (0%) | NA | 1 (0.6%) | 15(1.5%) | 1 (2.4%) | 0 (0%) | 0 (0%) | 0 (0%) | (, | 5 (1.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| Years since diagnosis | NA | NA | NA | NA | 1 (0.4%) | NA | NA | 0 (0%) | 1 (0.1%) | NA | NA | NA | 44 (22.3%) | NA | NA | NA | NA | 7 (2.2%) | NA | NA |
| Level of education | 9 (5.8%) | 0 (0%) | 11(3.3%) | NA | NA | 0 (0%) | 1 (0.4%) | NA | 30(2.9%) | 1 (2.4%) | NA | NA | 11 (5.6%) | 2 (0.7%) | 116 (32.4%) | 0 (0%) | 2 (0.5%) | 4 (1.3%) | NA | NA |
| Living status | 0 (0%) | 0 (0%) | 5 (1.5%) | 0 (0%) | 0 (0%) | NA | 0 (0%) | NA | NA | 0 (0%) | 0 (0%) | 0 (0%) | 24 (12.2%) | 0 (0%) | 116 (32.4%) | 1 (0.7%) | NA | 0 (0%) | NA | NA |
| Clusters of comorbid conditions | NA | 0 (0%) | 0 (0%) | 0 (0%) | 18(7.5%) | 0 (0%) | NA | 0 (0%) | 0 (0%) | 2 (4.8%) | 0 (0%) | NA | ` , | 3 (1.1%) | ` / | 0 (0%) | 0 (0%) | 2 (0.6%) | 0 (0%) | 0 (0%) |
| Outcomes | | | | | | | | | | | | | | | | | | | | |
| HF-related quality of life 6 months | NA | NA | NA | 104 (63.0%) | NA | 66 (10.9%) | 67 (25.2%) | NA | 315 (30.8%) | 13 (31.0%) | NA | 6 (5.9%) | NA | NA | 173 (48.3%) | 30 (22.2%) | 166 (40.9%) | 47 (14.8%) | NA | NA |
| HF-related quality of life 12 months | 40 (25.8%) | NA | NA | 130 (78.8%) | 67 (27.9%) | 89 (14.7%) | NA | NA | 361 (35.3) | 15 (35.7%) | 25 (16.3%) | 10 (9.8%) | 17 (8.6%) | NA | NA | NA | 190 (46.8%) | 61 (19.2%) | 43 (40.6%) | NA |
| Mortality - time-to-event | NA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (1.1%) | NA | 1 (0.1%) | 0 (0%) | NA | NA | 3 (1.5%) | 8 (2.8%) | 0 (0%) | 0 (0%) | NA | NA | 0 (0%) | 0 (0%) |
| Mortality 6 months | NA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 13 (4.9%) | 0 (0%) | 0 (0%) | 0 (0%) | NA | 0 (0%) | 0 (0%) | 7 (2.5%) | 0 (0%) | 0 (0%) | 0 (0%) | NA | 0 (0%) | 14 (5.1%) |
| Mortality 12 months | NA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 23 (8.6%) | NA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 7 (2.5%) | NA | NA | 0 (0%) | NA | 0 (0%) | NA |
| All-cause hospitalization time-to-event | NA | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.4%) | 0 (0%) | 3 (1.1%) | NA | 0 (0%) | 0 (0%) | NA | NA | NA | NA | 0 (0%) | 0 (0%) | NA | NA | 0 (0%) | 0 (0%) |
| All-cause hospitalization 6 months | NA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (1.1%) | 0 (0%) | 0 (0%) | 0 (0%) | NA | NA | NA | NA | 0 (0%) | 0 (0%) | NA | 40 (12.6%) | 0 (0%) | 0 (0%) |
| All-cause hospitalization 12 months | NA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (1.1%) | NA | 0 (0%) | 0 (0%) | NA | NA | 19(9.6%) | 7 (2.5%) | NA | NA | 0 (0%) | 42 (13.2%) | 0 (0%) | NA |
| HF-related hospitalization time-to-event | NA | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.4%) | 0 (0%) | NA | NA | 0 (0%) | 0 (0%) | NA | NA | NA | NA | 0 (0%) | 0 (0%) | NA | NA | NA | 1 (0.4%) |
| HF-related hospitalization 6 months | NA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | NA | 0 (0%) | 0 (0%) | 0 (0%) | NA | 3 (2.9%) | NA | NA | 0 (0%) | 0 (0%) | NA | NA | NA | 1 (0.4%) |
| HF-related hospitalization 12 months | NA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | NA | NA | 0 (0%) | 0 (0%) | NA | 3 (2.9%) | 28 (14.2%) | NA | NA | NA | 0 (0%) | NA | 0 (0%) | NA |

Table S3: Multivariable analysis of effects of characteristics of self-management interventions in

patients with heart failure included in the individual patient data meta-analysis.

| Outcome | N | n | Variable | | Effect | 95% CI | | | | |
|----------------------------|------|----------|-------------------------------|------|--------|---------------|--|--|--|--|
| | | patients | S | size | | | | | | |
| HF-related quality of life | | | | | | | | | | |
| 6 months follow-up | | | No significant characteristic | | | | | | | |
| 12 months follow-up | | | No significant characteristic | | | | | | | |
| Mortality | | | | | | | | | | |
| Time to event | 14 | 4312 | Duration (per month) | HR | 0.95 | (0.92 - 0.99) | | | | |
| | | | Peer contact | | 1.77 | (1.13-2.78) | | | | |
| 6 months follow-up | 17 | 4985 | Intensity (per contact) | RR | 0.95 | (0.93-0.97) | | | | |
| r | | | Peer contact | | 2.52 | (1.40-4.54) | | | | |
| 12 months follow-up | | | No significant characteristic | | | | | | | |
| All-cause hospitalizat | tion | | | | | | | | | |
| Time to first event | 12 | 3833 | Standardized training | HR | 0.95 | (0.61-1.49) | | | | |
| | | | Keeping logs | | 1.50 | (1.16-1.94) | | | | |
| | | | Goal-setting skills | | 1.79 | (1.20-2.66) | | | | |
| 6 months follow-up | 14 | 4238 | Standardized training | RR | 1.89 | (0.96-3.71) | | | | |
| 12 months follow-up | 13 | 4262 | Standardized training | RR | 1.26 | (0.95-1.67) | | | | |
| 1 | | | Keeping logs | | 1.18 | (0.97-1.44) | | | | |
| | | | Goal-setting skills | | 1.62 | (1.15-2.28) | | | | |
| HF-related hospitalization | | | | | | | | | | |
| Time to first event | 10 | 3461 | Duration (per month) | HR | 0.93 | (0.90-0.96) | | | | |
| | | | Standardized training | | 0.55 | (0.29-1.08) | | | | |
| | | | Multidisciplinary team | | 0.91 | (0.64-1.29) | | | | |
| | | | Keeping logs | | 2.24 | (1.40-3.57) | | | | |
| 6 months follow-up | 12 | 3741 | Duration (per month) | RR | 0.85 | (0.78-0.92) | | | | |
| 12 months follow-up | 11 | 3503 | Goal-setting skills | RR | 2.02 | (1.19-3.43) | | | | |

HR=hazard ratio; RR=risk ratio.

Results are only presented if program characteristic showed an effect with P<0.05 in the primary analysis.

Table S4: Sensitivity analysis by including published main effects of eligible studies without individual patient data available.

| | | In | ndividual | patient data only | Pooled analysis of individual patient data and published effects | | | |
|----------------------------|--------|--------------|---------------|----------------------|--|---------------|----------------------|--|
| | Effect | Stu- dies | Pa- tients | Effect size (95% CI) | Stu- dies | Pa- tients | Effect size (95% CI) | |
| HF-related quality of life | | | | | | | | |
| 6 months follow-up | SMD | 10 | 3419 | 0.13 (0.00-0.26) | 14 | 3816 | 0.15 (0.04-0.26) | |
| 12 months follow-up | SMD | 11 | 3356 | 0.15 (0.00-0.30) | 17 | 4370 | 0.14 (0.03-0.26) | |
| Mortality | | | | | | | | |
| Time to event | HR | 14 | 4312 | 0.91 (0.79-1.04) | 17 | 5326 | 0.89 (0.78-1.01) | |
| 6 months follow-up | RR | 17 | 4985 | 0.83 (0.66-1.05) | 20 | 5999 | 0.81 (0.66-0.98) | |
| 12 months follow-up | RR | 14 | 4204 | 0.86 (0.72-1.03) | 21 | 5450 | 0.88 (0.78-1.01) | |
| All-cause hospitalization | | | | | | | | |
| Time to first event | HR | 12 | 3833 | 0.93 (0.85-1.03) | 14 | 4699 | 0.93 (0.85-1.00) | |
| 6 months follow-up | RR | 14 | 4329 | 0.92 (0.83-1.01) | 17 | 5279 | 0.86 (0.66-1.13) | |
| 12 months follow-up | RR | 13 | 4266 | 0.95 (0.87-1.04) | 20 | 5512 | 0.91 (0.81-1.02) | |
| HF-related hospitalization | | | | | | | | |
| Time to first event | HR | 10 | 3461 | 0.80 (0.69-0.92) | 12 | 4327 | 0.79 (0.69-0.90) | |
| 6 months follow-up | RR | 12 | 3741 | 0.81 (0.66-0.99) | 14 | 4607 | 0.78 (0.66-0.92) | |
| 12 months follow-up | RR | 11 | 3503 | 0.82 (0.64-1.05) | 15 | 4126 | 0.77 (0.64-0.92) | |

CI=confidence interval; HF=heart failure; HR=hazard ratio; RR=risk ratio; SMD=standardized mean difference.

Table S5: Sensitivity analysis of effects of characteristics of self-management interventions in patients

with heart failure included in the individual patient data meta-analysis.

| " ton near t junion t | e inciaaea in ine inaiviaai | at patient at | OLDER STUDI | | RECENT STUDIES (N=10) | | |
|---|---|-------------------|--|-------------------------------|--|-------------------------------|--|
| Outcome | Analysis | Effect measure | Effect (95% CI) | P-value hetero- geneity | Effect (95% CI) | P-value hetero- geneity | |
| <i>Mortality</i> Time to event | Duration (per month) | HR | 0.96 (0.94-0.98) | 0.001 | 0.98 (0.94-1.02) | 0.504 | |
| | Peer contact No peer contact | | NA 0.74 (0.59-0.92) | | 1.36 (0.68-2.69) 0.96 (0.80-1.15) | 0.334 | |
| 6 months follow-up | Intensity (per contact) Peer contact No peer contact | RR | 0.96 (0.94-0.99) NA 0.80 (0.59-1.08) | 0.014 | 0.98 (0.95-1.01) 1.46 (0.57-3.72) 0.78 (0.51-1.18) | 0.157 0.226 | |
| 12 months follow-up | No significant characteristic | ic | | | | | |
| All-cause hospitali Time to first event | zation Standardized training Heterogeneous training | HR | 0.85 (0.71-1.03) 0.65 (0.50-0.84) | 0.092 | 1.10 (0.97-1.26) 0.79 (0.57-1.08) | 0.056 | |
| | Keeping logs No logs | | 1.05 (0.78-1.40) 0.69 (0.58-0.83) | 0.017 | 1.13 (0.97-1.31) 0.92 (0.75-1.14) | 0.131 | |
| | Goal-setting skills No goal-setting skills | | NA 0.77 (0.66-0.90) | | 1.26 (0.96-1.66) 1.00 (0.88-1.15) | 0.143 | |
| 6 months follow-up | Standardized training Heterogeneous training | RR | 0.91 (0.76-1.09) 0.66 (0.52-0.84) | 0.037 | 1.03 (0.91-1.16) 0.88 (0.66-1.18) | 0.334 | |
| 12 months follow-up | Standardized training Heterogeneous training | RR | 0.86 (0.73-1.01) 0.78 (0.64-0.94) | 0.417 | 1.10 (0.97-1.26) 0.88 (0.71-1.10) | 0.084 | |
| | Keeping logs No logs | | 0.90 (0.73-1.11) 0.79 (0.68-0.92) | 0.308 | 1.13 (0.96-1.34) 1.00 (0.84-1.20) | 0.332 | |
| | Goal-setting skills No goal-setting skills | | NA 0.82 (0.73-0.92) | | 1.21 (1.02-1.43) 0.95 (0.85-1.07) | 0.024 | |
| HF-related hospital Time to first event | | HR | 0.94 (0.92-0.96) | <0.001 | 1.00 (0.99-1.02) | 0.664 | |
| | Standardized training Heterogeneous training | | 0.63 (0.47-0.84) 0.47 (0.34-0.67) | 0.217 | 1.04 (0.85-1.28) 0.97 (0.61-1.53) | 0.776 | |
| | Multidisciplinary team Single interventionist | | 0.67 (0.29-1.55) 0.55 (0.44-0.69) | 0.654 | 1.05 (0.82-1.34) 1.01 (0.81-1.27) | 0.851 | |
| | Keeping logs No logs | | 0.81 (0.54-1.21) 0.47 (0.36-0.62) | 0.031 | 1.06 (0.85-1.32) 0.97 (0.68-1.39) | 0.686 | |
| 6 months follow-up | Duration (per month) | RR | 0.93 (0.89-0.97) | 0.014 | 0.99 (0.92-1.04) | 0.657 | |
| 12 months follow-up | Goal-setting skills No goal-setting skills | RR | NA 0.58 (0.46-0.73) | | 1.20 (0.78-1.85) 1.02 (0.55-1.90) | 0.664 | |

CI=confidence interval; HR=hazard ratio; NA=not applicable since no studies in category; RR=risk ratio. Results are only presented if program characteristic showed an effect with P<0.05 in the primary analysis.